MKI67 and renal cell carcinoma: To this end, two recent innovative studies have reported the development of a prognostic model that incorporates a panel of malignancy-associated biomarkers (which includes p53, CA9, Ki67, vimentin, CA12, PTEN and gelosin) with standard clinical parameters and where the resultant ‘clinical/molecular marker’ model, better predicts survival of patients with RCC (Kim et al, 2004, 2005).